Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DEP: Theophylline for LPS-Induced Depressive Symptoms
NCT04309877Phase 1Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of theophylline in major depressive disorder (MDD) (4 arms), sponsored by University of California, Los Angeles. Primary endpoint: Change in depressed mood from baseline at 6 hours. Planned start Mar 2023; status: withdrawn.
02
Drugs
theophylline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04309877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309877.